Anti Inflammatory News and Research

RSS

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Findings of a preliminary study published in The Lancet Respiratory Medicine suggest that a patient’s own bone-marrow stromal (stem) cells could be used to treat multidrug-resistant (MDR) and extensively-drug (XDR) tuberculosis.

10 Jan 2014

Research: SLPI protein produced by body in response to injury plays vital role in patients with ALF

Findings published in the American Association for the Study of Liver Diseases journal, Hepatology, indicate that infection, the commonest cause of mortality in patients with acute liver failure, may be decreased by inhibiting the activity of a protein found in saliva called SLPI.

10 Jan 2014

Nano-luteolin has immense potential for future studies of chemoprevention, say researchers

Researchers at the Winship Cancer Institute of Emory University have discovered a more effective drug delivery system using nanotechnology that could one day significantly affect cancer prevention.

8 Jan 2014

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for its drug candidate, Erdosteine, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.

7 Jan 2014

Synthetic cannabinoid molecule created for osteoarthritis

Chemical compounds synthesised in the laboratory, similar to those found in cannabis, could be developed as potential drugs to reduce the pain of osteoarthritis.

7 Jan 2014

Plant-based milk for people with lactose or gluten intolerance

Researchers at the Universitat Politècnica de València have obtained new products fermented with probiotic bacteria from grains and nuts - what is known as plant-based or vegetable "milks" - which are an alternative to conventional yogurts.

6 Jan 2014

Macrophages invade diabetic pancreatic tissue during early stages of type 2 diabetes

As people's waistlines increase, so does the incidence of type 2 diabetes. Now scientists have a better understanding of exactly what happens in the body that leads up to type 2 diabetes, and what likely causes some of the complications related to the disease. Specifically, scientists from Denmark have found that in mice, macrophages, a specific type of immune cell, invade the diabetic pancreatic tissue during the early stages of the disease.

2 Jan 2014

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Genzyme, a Sanofi company, announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration for its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.

30 Dec 2013

Consumption of nuts promotes health and longevity, finds study

In a study published November 20, 2013 in the New England Journal of Medicine1, researchers looked at the association of nut consumption with total and cause-specific mortality among 76,464 women in the Nurses' Health Study and 42,498 men in the Health Professionals Follow-up Study. Consumption of nuts, including tree nuts (such as pistachios, almonds, Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, and walnuts), was inversely associated with total mortality in both men and women, independent of other predictors for death.

28 Dec 2013

Nonsteroidal anti-inflammatory agent delays neuropathy progression, preserves quality of life

Among patients with familial amyloid polyneuropathy, a lethal, genetic neurodegenerative disease, use of the nonsteroidal anti-inflammatory agent diflunisal compared with placebo for 2 years reduced the rate of progression in neurological impairment and preserved quality of life, according to a study appearing in the December 25 issue of JAMA.

27 Dec 2013

Diflunisal drug reduces neurological decline in patients with familial transthyretin amyloidosis

A recent study led by researchers from the Amyloidosis Center at Boston University School of Medicine and Boston Medical Center demonstrates that diflunisal, a generic anti-inflammatory drug, successfully reduced neurological decline and preserved the quality of life in patients with familial transthyretin amyloidosis. Diflunisal is an inexpensive and safe medication marketed over the past 40 years for arthritis and pain.

25 Dec 2013

Researchers identify potential therapy for meibomian gland dysfunction

Meibomian gland dysfunction is the leading cause of dry eye disease, which affects tens of millions of Americans. However, there is no FDA-approved treatment for MGD. Researchers from the Schepens Eye Research Institute/Massachusetts Eye and Ear and Harvard Medical School have just identified a potential therapy.

24 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Physicians at the Ruhr-Universität Bochum (RUB) have been investigating if established anti-epilepsy drugs have anti-inflammatory or pro-inflammatory properties - an effect for which these pharmaceutical agents are not usually tested.

20 Dec 2013

Study: Standard treatment approaches yield modest to large improvement in TMD patients

empromandibular pain disorders (TMDs) are characterized by a dysfunction of the TMD joint and cause orofacial pain, masticatory dysfunction or both.

20 Dec 2013

Researchers discover cancer-killing properties of frankincense in ovarian cancer

Researchers from the University of Leicester have, for the first time, demonstrated the potential of treating ovarian cancer using the Christmas gift frankincense.

20 Dec 2013

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Genzyme, a Sanofi company, announced today that the Australian Therapeutic Goods Administration has approved Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses.

19 Dec 2013

Nuvo Research, NovaMedica enter into agreement to market Pennsaid products in Russia

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC, a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States.

19 Dec 2013

UT Southwestern receives $10M grant to find effective treatments for alcoholic hepatitis

UT Southwestern Medical Center has launched the local arm of a national, multicenter study aimed at finding more effective treatments for alcoholic hepatitis, a disease of the liver that often leads to cirrhosis and death in severe cases.

19 Dec 2013

Anti Inflammatory News and Research

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Research: SLPI protein produced by body in response to injury plays vital role in patients with ALF

Nano-luteolin has immense potential for future studies of chemoprevention, say researchers

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Synthetic cannabinoid molecule created for osteoarthritis

Plant-based milk for people with lactose or gluten intolerance

Macrophages invade diabetic pancreatic tissue during early stages of type 2 diabetes

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Consumption of nuts promotes health and longevity, finds study

Nonsteroidal anti-inflammatory agent delays neuropathy progression, preserves quality of life

Diflunisal drug reduces neurological decline in patients with familial transthyretin amyloidosis

Researchers identify potential therapy for meibomian gland dysfunction

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Study: Standard treatment approaches yield modest to large improvement in TMD patients

Researchers discover cancer-killing properties of frankincense in ovarian cancer

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Nuvo Research, NovaMedica enter into agreement to market Pennsaid products in Russia

UT Southwestern receives $10M grant to find effective treatments for alcoholic hepatitis

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News